MedTrace Logo

Multicenter iTBS Neuromodulation for PTSD Treatment

NCT06434766 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-04-24

No results posted yet for this study

Summary

The proposed study aims to evaluate the efficacy of intermittent theta-burst transcranial magnetic stimulation (iTBS) targeting primary motor cortex (M1) as adjunct treatment for PTSD patients. The primary outcome measure includes changes in PTSD symptom severity, with secondary outcome measures focusing on negative moods improvements, quality of life and social/occupation functioning and functional connectivity of the brain.

Conditions

Interventions

DEVICE

sham stimulation

sham theta-burst transcranial magnetic stimulation

DEVICE

intermittent theta-burst stimulation (iTBS)

intermittent theta-burst transcranial magnetic stimulation

Sponsors & Collaborators

  • Shanghai Mental Health Center

    collaborator OTHER

  • The Affiliated Kangning Hospital of Ningbo University

    collaborator UNKNOWN

  • The First Affiliated Hospital of Anhui Medical University

    collaborator OTHER

  • Tongji Hospital

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Yuan Shen, M.D., Ph.D. · Shanghai Mental Health Center

  • Chang Yu, M.D. · The Affiliated Kangning Hospital of Ningbo University

  • Kai Wang, M.D., Ph.D. · The First Affiliated Hospital of Anhui Medical University

  • Xiaoming Li, M.D., Ph.D. · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-30
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06434766 on ClinicalTrials.gov